Atlas Trials

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Clinical trial NCT00243087 · COMPLETED

Trial details

NCT number
NCT00243087
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma
Start date
2005-07-01
Primary completion
2008-08-01
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.